The European schizophrenia outpatient health outcomes (SOHO) study: Baseline findings of the Spanish sample;Estudio observacional paneuropeo de la efectividad de la olanzapina frente a otros antipsicóticos (SOHO): Resultados basales de la muestra española

Actas Espanolas de Psiquiatria

Volumn 32, Issue 4, 2004, Pages 227-235

  Ciudad, A ^a   Prieto, L ^a   Olivares, J M ^b   Montejo, A L ^c   Ros, S ^d   Novick, D ^e  

^a ELI LILLY AND COMPANY   (Spain)

^b Servicio de Psiquiatria   (Spain)

^c Biomedical Research Institute of Salamanca IBSAL   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic agents; Observational; Outpatients; Schizophrenia; Utilization patterns

Indexed keywords

OLANZAPINE;

ADULT; ARTICLE; DRUG EFFECT; DRUG TOLERABILITY; EUROPE; FEMALE; HEALTH SURVEY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; OUTPATIENT; PATIENT SATISFACTION; POPULATION RESEARCH; PROSPECTIVE STUDY; SCHIZOPHRENIA; SPAIN; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; EUROPE; FEMALE; HUMANS; MALE; OBSERVATION; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 4143120092     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, et al. Defining treatment-refractoriness in schizophrenia. Schizophr Bull 1990;16:551-61.
2. Kane JM. Schizophrenia. N Engl J Med 1996;334:34-41.
3. Weiden PJ, Shaw E, Mann JJ. Causes of neuroleptic non-compliance. Psychiatr Ann 1986;16:571-5.
4. Beasley CM Jr, Tollefson GD, Tran P, Satterlee W, Sange T, Hamilton S, and the Olanzapine HGAD Study Group. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:105-18.
5. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Tamura RN, Krueger JA, et al. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:157-65.
6. Chouinard G, Jones B, Remington G. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients. J Clin Psychoparmacol 1993;13:25-40.
7. Arvanitis LA, Miller BG, Bopison RL. Multiple fixed doses of seroquel (quetiapine) in patients with acute exacerbation of schizophreni - a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46.
8. Purdon SE, Jones BD, Stip E. Neuropsychological change in early phase schizophrenia during 12 months of treatment with Olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000;57:249-58.
9. Beasley CM Jr, Dellva MA, Tamura RN. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with Olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30.
10. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new anti- psychotic olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomised controlled trials. Schizophr Res 1999;35:51-68.
11. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86.
12. Concato J, Shah N, Horwitz RJ. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92.
13. Rothwell PM. Can overall results of clinical trials be applied to all patients. Lancet 1995;345:1616-9.
14. Thornley B, Adams C. Content collaborative working group on clinical trial evaluations: clinical development of atypical antipsychotics: research design and evaluation. J Clin Psychiatry 1998;59(Suppl 12):10-6.
15. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998;317:1181-4.
16. Buckley PF. Substance abuse in schizophrenia: a review. J Clin Psychiatry 1998;59:26-30.
17. Lasagna L. A plea for the «naturalistic» study of medicines. Eur J Clin Pharmacol 1974;7:153-4.
18. Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003;107:222-32.
19. Haro JM, Kamath SA, Ochoa S, on behalf of the SOHO Study Group. The Clinical Global Impression- Schizophrenia (CGI-SCH) scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 2003;107(Suppl 416):16-23.
20. Badía X, Roset M, Herdman. The Spanish version of EuroQol: a description and its applications. Med Clin 1999;112:s79-s86.
21. Prieto L, Sacristán JA, Hormaechea JA, Gómez JC. Euroqol-5D (a generic health-related quality of life measure): psychometric validation in a sample of schizophrenic patients. Eur Neuropsychopharmacol 2002;12(Suppl 3): 300.
22. a ed. Washington: American Psychiatric Press, 1994.
23. Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S. The social functioning scale: the development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry 1990;157:853-59.
24. SAS OnlineDoc®, Version 8. Cary, NC: SAS Institute Inc, 2000.
25. Becker T, Knapp M, Knudsen HC. The EPSILON study of schizophrenia in five European countries. Design and methodology for standardizing outcome measures and comparing patterns of care and service costs. Br J Psychiatry 1999;175:514-21.
26. Gómez JC, Sacristán JA, Hernández J. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO study). J Clin Psychiatry 2000;61:335-43.
27. The Expert Consensus Panels. The expert consensus guideline series: treatment of schizophrenia 1999. J Clin Psychiatry 1999;60(Suppl 11):1-82.
28. National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance No. 43. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London: NICE, 2002; p. 2. http://www.nice.org. uk/pdf/ANTIPSYCHOTICfinal-guidance.pdf.